Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
PepGen Inc. - Common Stock
(NQ:
PEPG
)
8.550
-0.270 (-3.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PepGen Inc. - Common Stock
< Previous
1
2
3
4
Next >
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
September 19, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
August 20, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
August 20, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
PEPG Stock Earnings: PepGen Misses EPS for Q2 2024
August 08, 2024
PEPG stock results show that PepGen missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 08, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 02, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher
July 31, 2024
Via
Benzinga
Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings
July 31, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
May 14, 2024
PEPG stock results show that PepGen beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
March 06, 2024
PEPG stock results show that PepGen beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
July 31, 2024
From
The Schall Law Firm
Via
Business Wire
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
July 30, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
July 02, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Announces Executive Team Promotions
June 11, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
PepGen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 12, 2024
Via
Benzinga
Insiders Buying GameStop And 2 Other Stocks
April 10, 2024
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
PepGen to Participate in Upcoming Investor Conferences
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
March 07, 2024
Via
Benzinga
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 06, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 04, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 20, 2024
From
PepGen Inc.
Via
GlobeNewswire
Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
February 14, 2024
Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 07, 2024
Via
Benzinga
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
February 07, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
February 06, 2024
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy
Via
MarketBeat
Top 4 Health Care Stocks That May Crash This Quarter
February 02, 2024
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.